The UKCPA Heart Failure Committee and the British Society for Heart Failure have published prescribing advice on a new licensed product of metolazone – Xaqua -, including the rationale for prescribing this instead of the unlicensed metolazone product.
The advisory statement also includes information on the product’s bioavailability, potential allergies and intolerance, and advice and actions for clinical practitioners.
